Connor, Clark & Lunn Investment Management (CC&L)
BEAM icon

Connor, Clark & Lunn Investment Management (CC&L)’s Beam Therapeutics BEAM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-42,687
Closed -$2.03M – 1212
2022
Q3 		$2.03M Buy
+42,687
New +$2.44M 0.01% 493

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s BEAM Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Beam Therapeutics (BEAM) in Q4 2022, closing a stake of 42,687 shares — an estimated $2.03M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BEAM in Q3 2022 and held it in 1 quarter. The position peaked at $2.03M in Q3 2022. 209 funds tracked by Wall St. Rank hold BEAM as of Q4 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Beam Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 42,687 Beam Therapeutics shares in Q4 2022, an estimated $2.03M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Beam Therapeutics in Q3 2022 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Beam Therapeutics position peaked at $2.03M in Q3 2022.
  • 209 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.